ActoGeniX: Optimized for the gut

Making protein and peptide drugs orally available is an ongoing challenge. ActoGeniX N.V. thinks its TopAct genetically modified Lactococcus bacteria will be appropriate for mucosal delivery of proteins and peptides in the gut to treat gastrointestinal diseases.

TopAct was developed at the Flanders Interuniversity Institute of Biotechnology (VIB), which contributed the technology to ActoGeniX (Ghent, Belgium) in exchange for shares in the company, CEO

Read the full 641 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE